These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 8839913)

  • 1. Peripheral nerve entrapment: an unusual adverse event with high-dose interleukin-2 therapy.
    Sikora SS; Samsonov ME; Dookeran KA; Edington H; Lotze MT
    Ann Oncol; 1996 Jul; 7(5):535-6. PubMed ID: 8839913
    [No Abstract]   [Full Text] [Related]  

  • 2. Interleukin-2 in the treatment of renal cell carcinoma and malignant melanoma.
    Eklund JW; Kuzel TM
    Cancer Treat Res; 2005; 126():263-87. PubMed ID: 16209070
    [No Abstract]   [Full Text] [Related]  

  • 3. High-dose interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma: still the standard.
    Dutcher JP
    Oncology (Williston Park); 2011 Apr; 25(5):427-8. PubMed ID: 21710841
    [No Abstract]   [Full Text] [Related]  

  • 4. Interleukin 2 in cancer therapy.
    Antony GK; Dudek AZ
    Curr Med Chem; 2010; 17(29):3297-302. PubMed ID: 20712575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-2.
    Med Lett Drugs Ther; 1990 Sep; 32(826):85-6. PubMed ID: 2202892
    [No Abstract]   [Full Text] [Related]  

  • 6. Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma.
    Du Bois JS; Trehu EG; Mier JW; Shapiro L; Epstein M; Klempner M; Dinarello C; Kappler K; Ronayne L; Rand W; Atkins MB
    J Clin Oncol; 1997 Mar; 15(3):1052-62. PubMed ID: 9060545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Management of adverse events with interferon and interleukin-2].
    Takahashi S
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():322-8. PubMed ID: 25831776
    [No Abstract]   [Full Text] [Related]  

  • 8. High-dose interleukin-2 in metastatic disease: renal cell carcinoma and melanoma.
    Dutcher J
    Oncology (Williston Park); 2002 Nov; 16(11 Suppl 13):3. PubMed ID: 12469933
    [No Abstract]   [Full Text] [Related]  

  • 9. Angioneurotic oedema and urticaria during therapy with interleukin-2 (IL-2).
    Baars JW; Wagstaff J; Hack CE; Wolbink GJ; Eerenberg-Belmer AJ; Pinedo HM
    Ann Oncol; 1992 Mar; 3(3):243-4. PubMed ID: 1586626
    [No Abstract]   [Full Text] [Related]  

  • 10. A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part II: Immunological aspects.
    Vlasveld LT; Hekman A; Vyth-Dreese FA; Rankin EM; Scharenberg JG; Voordouw AC; Sein JJ; Dellemijn TA; Rodenhuis S; Melief CJ
    Br J Cancer; 1993 Sep; 68(3):559-67. PubMed ID: 8353046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarkers of therapeutic response in melanoma and renal cell carcinoma: potential inroads to improved immunotherapy.
    Kirkwood JM; Tarhini AA
    J Clin Oncol; 2009 Jun; 27(16):2583-5. PubMed ID: 19364958
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety and clinical effect of subcutaneous human interleukin-21 in patients with metastatic melanoma or renal cell carcinoma: a phase I trial.
    Schmidt H; Brown J; Mouritzen U; Selby P; Fode K; Svane IM; Cook GP; Mollerup DH; Geertsen PF
    Clin Cancer Res; 2010 Nov; 16(21):5312-9. PubMed ID: 20959407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rigor prophylaxis in stage IV melanoma and renal cell carcinoma patients treated with high dose IL-2.
    Khong B; Lawson BO; Ma J; McGovern C; Van Atta JK; Ray A; Khong HT
    BMC Cancer; 2018 Oct; 18(1):1007. PubMed ID: 30342473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunological effects of alternative weekly interferon-alpha-2b and low dose interleukin-2 in patients with cancer.
    Fiorentino B; Di Stefano P; Giuliani C; Amatetti C; Tinari N; Natoli C; Garufi C; Iacobelli S
    Br J Cancer; 1992 Nov; 66(5):981-3. PubMed ID: 1419647
    [No Abstract]   [Full Text] [Related]  

  • 15. Weighing the evidence for immune therapy and targeted therapy in renal cancer and melanoma.
    Dorff TB; Wong MK
    Oncology (Williston Park); 2013 Jul; 27(7):691-2, 694. PubMed ID: 23977764
    [No Abstract]   [Full Text] [Related]  

  • 16. A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part I: Clinical aspects.
    Vlasveld LT; Rankin EM; Hekman A; Rodenhuis S; Beijnen JH; Hilton AM; Dubbelman AC; Vyth-Dreese FA; Melief CJ
    Br J Cancer; 1992 May; 65(5):744-50. PubMed ID: 1586602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-2: clinical applications.
    Atkins MB
    Semin Oncol; 2002 Jun; 29(3 Suppl 7):12-7. PubMed ID: 12068383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is IL-2 still indicated for melanoma and RCC? What a question to ask!
    Hamid O
    Oncology (Williston Park); 2013 Jul; 27(7):695, 701. PubMed ID: 23977765
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of acute toxicity and mortality after two different dosing regimens of high-dose interleukin-2 for patients with metastatic melanoma.
    Alwan LM; Grossmann K; Sageser D; Van Atta J; Agarwal N; Gilreath JA
    Target Oncol; 2014 Mar; 9(1):63-71. PubMed ID: 23609056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myositis following treatment with high dose interleukin-2 for malignancy.
    Finger DR; Plotz PH; Heywood G
    J Rheumatol; 1995 Nov; 22(11):2188. PubMed ID: 8596171
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.